|Systematic (IUPAC) name|
|14px (what is this?)|
The first material regarding the synthesis and effects of 5-MeO-DALT was sent from Alexander Shulgin to a researcher in May 2004, after which it was circulated online. In June 2004 5-MeO-DALT became available from internet research chemical vendors. In August 2004 the synthesis and effects of 5-MeO-DALT were published by Erowid.
Doses ranging from 12–20 mg were tested by Alexander Shulgin's research group.
There are numerous anecdotal reports of users consuming dosages far in excess of those tested by Alexander Shulgin, although there is no published literature on the toxicity of 5-MeO-DALT.
5-MeO-DALT became a Class A drug in the UK on January 7th 2015 after an update to the tryptamine blanket ban.
Sveriges riksdag added 5-MeO-DALT to schedule I ("substances, plant materials and fungi which normally do not have medical use") as narcotics in Sweden as of May 1, 2012, published by Medical Products Agency in their regulation LVFS 2012:6 listed as 5-MeO-DALT N-allyl-N-[2-(5-metoxi-1H-indol-3-yl)etyl]-prop-2-en-1-amin.
5-MeO-DALT is not scheduled at the federal level in the United States, but it is likely that it could be considered an analog of 5-Meo-DiPT or another tryptamine, in which case purchase, sale, or possession could be prosecuted under the Federal Analog Act.
- , Morris, H. (11 May 2010). "The Last Interview With Alexander Shulgin". Vice Magazine. Retrieved 2011-02-24.
- "厚生労働省：平成１8年度無承認無許可医薬品等買上調査の結果について". Retrieved 2012-06-26. Invalid language code.
- §1308.11 Schedule I.
- Florida Statutes - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL